Modality
mAb
MOA
VEGFi
Target
GLP-1R
Pathway
mTOR
NASHWM
Development Pipeline
Preclinical
~Feb 2023
→ ~May 2024
Phase 1
Aug 2024
→ Apr 2031
Phase 1Current
NCT08494268
1,414 pts·NASH
2024-09→2031-04·Not yet recruiting
NCT08360418
688 pts·NASH
2024-08→2029-02·Completed
2,102 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-02-072.9y awayInterim· NASH
2031-04-275.1y awayInterim· NASH
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1
Complet…
P1
Not yet…
Catalysts
Interim
2029-02-07 · 2.9y away
NASH
Interim
2031-04-27 · 5.1y away
NASH
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08494268 | Phase 1 | NASH | Not yet recr... | 1414 | PANSS |
| NCT08360418 | Phase 1 | NASH | Completed | 688 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R |